Benjamin Aronbayev
Forest Hills, NYNPI 1265024525
Payments from drug & device makers
Across 282 payments — averaging $23.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Johnson & Johnson$905
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$564
- Ardelyx, Inc.$350
- Phathom Pharmaceuticals, Inc.$326
- Gilead$306
- plus $2K from 19 others
What the payments were for
- Food & beverage$6,51799%
- Education$991%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 90 | $2,478 |
| Johnson & Johnson | 31 | $905 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 31 | $564 |
| Ardelyx, Inc. | 16 | $350 |
| Phathom Pharmaceuticals, Inc. | 12 | $326 |
| Gilead | 20 | $306 |
| Takeda Pharmaceuticals U.S.A., Inc. | 17 | $305 |
| Sanofi | 9 | $198 |
| Intra-sana Laboratories | 5 | $194 |
| Intercept Pharmaceuticals, Inc. | 9 | $176 |
| Pfizer | 8 | $164 |
| Madrigal Pharmaceuticals | 9 | $149 |
| Ironwood Pharmaceuticals, Inc | 4 | $76 |
| Regeneron Healthcare Solutions, Inc. | 2 | $57 |
| Redhill Biopharma Inc. | 2 | $46 |
| Celltrion USA Inc. | 2 | $46 |
| Incyte Corporation | 2 | $42 |
| Janssen Scientific Affairs, LLC | 2 | $41 |
| Lilly USA, LLC | 2 | $40 |
| Ipsen Biopharmaceuticals, Inc | 2 | $38 |
| Braintree Laboratories, Inc. | 2 | $35 |
| Bristol Myers Squibb | 2 | $32 |
| VYNE Pharmaceuticals Inc. | 1 | $18 |
| Exact Sciences | 1 | $17 |
| Novo Nordisk | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Creon$396
- LINZESS$394
- Tremfya$300
- STELARA$150
- IBSRELA$150
- Skyrizi$125
- VOQUEZNA$125
- Reltone 200 Mg$108
- GLYCATE$108
- Reltone 400 Mg$108
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CreonLipase/Protease/Amylase | 20 | $69,510 |
| LinzessLinaclotide | 98 | $62,695 |
| Dexlansoprazole DrDexlansoprazole | 159 | $57,571 |
| Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates | 148 | $8,269 |
| Mesalamine ErMesalamine | 12 | $5,082 |
| Tenofovir Disoproxil Fumarate | 14 | $4,144 |
| Famotidine | 135 | $2,070 |
| Pantoprazole Sodium | 167 | $1,790 |
| Ursodiol | 12 | $1,518 |
| Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl | 75 | $1,032 |
| Metronidazole | 17 | $931 |
| Omeprazole | 69 | $884 |
| Sucralfate | 29 | $561 |
| Dicyclomine Hcl | 21 | $508 |
| Hydrocortisone | 41 | $357 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieCreon, Linzess | $2,478 | $132,205118 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few providers in New Yorkon file to place this against a meaningful peer group, so we don't.
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.